Abstract
To evaluate the efficacy and toxicity of two different etoposide (VP-16) dosages (30 or 45 mg/kg) in combination with busulfan/cyclophosphamide as conditioning therapy followed by stem cell transplantation in acute myeloid leukemia (AML), 90 patients with AML received either 30 mg/kg (n = 60) or 45 mg/kg (n = 30) etoposide in combination with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg). The stem cell source was allogeneic related bone marrow (BM) (n = 53), allogeneic unrelated BM (n = 5), allogeneic unrelated peripheral blood (PBSC) (n = 2), syngeneic BM (n = 2), autologous BM purged (n = 9) or unpurged (n = 9), autologous PBSC (n = 10). fifty-six patients (62%) were in first cr, 26 (29%) were > first CR, and eight (9%) were transplanted in relapse. Principal toxicities in both groups were mucositis and hepatotoxicity. Forty-five mg/kg etoposide resulted in greater hepatic toxicity (P = 0.03), and a higher incidence of VOD (23 vs 12%, P = 0.04) and acute GVHD grade III/IV (13 vs 5%, NS). The treatment-related mortality was 17% in the 30 mg/kg group and 33% in the 45 mg/kg group, mainly due to infections, intestinal pneumonia and GVHD. Hematological recovery of leukocytes 1/nl was comparable in both groups (17 vs 16 days). After a median follow-up of 16 months 19% in the 30 mg/kg group and 23% in the 45 mg/kg group relapsed. In patients who had undergone allogeneic related bone marrow transplantation in first CR no relapses occurred after a median follow-up of 3 years. For all patients the 3-year estimated disease-free survival was 62% in the 30 mg/kg group and 40% in the 45 mg/kg group (P = 0.03). For patients in first CR who underwent allogeneic related stem cell transplantation the 3 year disease-free survivals were 80% and 66%, respectively (P = 0.4). We conclude that etoposide 30 mg/kg or 45 mg/kg in combination with busulfan/cyclophosphamide is a highly active regimen for bone marrow transplantation of patients with AML with a low relapse rate. However, conditioning with 30 mg/kg rather than 45 mg/kg etoposide resulted in less toxicity and a better overall survival due to a lower transplant-related mortality. Bone Marrow Transplantation (2000) 26, 711–716.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Weinstein HJ, Mayer RJ, Rosenthal DS et al. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update Blood 1983 62: 315–319
Cassileth PA, Lynch E, Hines JD et al. Varying intensity of postremission therapy in acute myeloid leukemia Blood 1992 79: 1924–1930
Büchner T, Urbanitz D, Hiddemann W et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia J Clin Oncol 1985 3: 1583–1589
Appelbaum FR . Allogeneic hematopoietic stem cell transplantation for acute leukemia Semin Oncol 1997 24: 114–123
Linker CA, Ries CA, Damon LE et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen Blood 1993 81: 311–318
Gorin NC, Najman A, Duhamel G . Autologous bone marrow transplantation in acute myeloid leukemia Lancet 1977 1: 1050
Tutschka PJ, Copelan EA, Klein JA et al. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen Blood 1987 70: 1382–1388
Körbling M, Hunstein W, Fliedner TM et al. Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia Blood 1989 74: 1898–1904
Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens Blood 1990 76: 1867–1871
Zander AR, Culbert S, Jagannath S et al. High-dose cyclophosphamide, BCNU, and VP-16 as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia Cancer 1987 59: 1083–1086
Mathe G, Schwarzenberg L, Pouillart P et al. Two epidophyllotoxin derivates VM 26 and VP16–213 in the treatment of leukemias, hematosarcomas, and lymphomas Cancer 1974 34: 985–991
Smith IE, Gerken ME, Clink HM, McElwain TJ . VP 16–213 in acute myelogenous leukemia Postgrad Med J 1976 52: 66–70
van Echo DA, Wiernik PH, Aisner J . High-dose VP 16–213 for treatment of patients with previously treated acute leukemia Cancer Clin Trials 1980 3: 325–328
Henwood JN, Brodgen RN . Etoposide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer Drugs 1990 39: 438–490
Stadtmauer EA, Casselith PA, Gale RP et al. Etoposide in leukemia, lymphoma and bone marrow transplantation Leuk Res 1989 13: 639–650
Wolff SN, McKay CM, Hande KR et al. High-dose VP16–213 and autologous bone marrow transplantation for refractory malignancies—a phase I study J Clin Oncol 1983 1: 701–705
Spitzer TR, Cottler-Fox M, Torrisi J et al. Escalating doses of etoposide with cyclophosphamide and fractionated TBI or busulfan conditioning for BMT Bone Marrow Transplant 1989 4: 559–565
Crilley P, Topolsky D, Styler MJ et al. Extramedullary toxicity of a conditioning regimen containing busulfan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogeneic bone marrow transplantation Bone Marrow Transplant 1995 15: 361–365
Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft vs host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 1974 18: 295–304
Zander AR, Zabelina T, Kröger N et al. Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow Bone Marrow Transplant 1999 23: 889–893
Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568
Kaplan E, Meier P . Non-parametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481
Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute non-lymphomic leukemia after treatment with busulfan and cyclophosphamide New Engl J Med 1983 309: 1347–1353
Tutschka PJ, Copelan EA, Klein JA et al. Bone marrow transplantation for leukemia following new busulfan and cyclophosphamide regime Blood 1987 70: 1382–1388
Blaise D, Maraninchi D, Michallet M et al. BuCy(120) vs TBI/Cy to prepare allo-BMT for CR1 AML: a follow-up of a study from GEGMO Bone Marrow Transplant 1999 23: (Suppl.1) 228
Ringden O, Labopin M, Tura S . A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukemia Br J Haematol 1996 93: 637–645
Hartmann AR, Williams SF, Dillon JJ . Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis Bone Marrow Transplant 1998 22: 439–443
Blume KG, Forman SJ, O’Donnel MR et al. Total body irradiation and high-dose etoposide: a new preparative regimen for bone marrow transplantation in patients with advanced hematological malignancies Blood 1987 69: 1015–1020
Schmitz N, Gassmann W, Rister M et al. Fractionated total body irradiation and high-dose VP 16–213 followed by allogeneic bone marrow transplantation in advanced leukemias Blood 1988 72: 1567–1573
Blume KG, Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group Study Blood 1993 81: 2187–2193
Vaughan WP, Dennison JD, Reed EC et al. Improved results of allogenic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy Bone Marrow Transplant 1991 8: 489–495
Chao NJ, Stein AS, Longo GD et al. Busulfan/etoposide-initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with AnLL Blood 1993 81: 319–323
Spitzer TR, Cottler-Fox M, Torrisi J et al. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation Bone Marrow Transplant 1989 4: 559–565
Zander AR, Berger C, Kröger N et al. High-dose chemotherapy with busulfan, cyclophosphamide and VP 16 as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission Clin Cancer Res 1997 3: 2671–2675
Acknowledgements
We thank the staff of the BMT unit for providing excellent care of our patients and the medical technicians for their excellent work in the BMT laboratory.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kröger, N., Zabelina, T., Sonnenberg, S. et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant 26, 711–716 (2000). https://doi.org/10.1038/sj.bmt.1702598
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702598
Keywords
This article is cited by
-
Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire
Bone Marrow Transplantation (2014)
-
Allo-SCT using BU, CY and melphalan for children with AML in second CR
Bone Marrow Transplantation (2013)
-
Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia
Bone Marrow Transplantation (2011)
-
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Bone Marrow Transplantation (2011)
-
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia
Acta Pharmacologica Sinica (2009)